Frontlight ResearchEarly access
Not yet taking people in GreecePhase 4
Cladribine Tablets and Immune Cell Contact Molecules in Relapsing Multiple Sclerosis
Tests cladribine tablets in adults with relapsing multiple sclerosis who are new to treatment.
Key facts
- Who runs it
- Aristotle University Of Thessaloniki
- Where
- Thessaloniki, GreeceSee the 2 sites
- Trial code
- Registry title
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 30 people, planned
- Started
- 20 Feb 2026
- Expected to end
- 20 Feb 2028
- Type of study
- Interventional
- Record updated
- 3 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with relapsing-remitting multiple sclerosis who have never been treated for it and will start cladribine tablets as prescribed by their doctor.
- Age
- 18 to 50 years old
- Sex
- All sexes
- Disease stage
- Relapsing-remitting multiple sclerosis (RRMS), diagnosed with a full workup in the 6 months before joining. No progressive MS.
- Earlier treatment
- Must not have had any other disease-modifying treatment (DMT) for MS before. Cladribine is prescribed by the treating doctor as in the approved MAVENCLAD product information in Greece.
Main reasons for not taking part
- Any reason in the product information that rules out cladribine tablets
- Other neurological disease
- History of alcohol or drug abuse that could interfere with taking part
- Taking part in another investigational study at the same time
- MS diagnosed more than 6 months before joining
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Patients with RRMS, age ≥18 and ≤50 years old
- Treatment naive
- Cladribine prescription per the decision of the treating physician and according to the approved MAVENCLAD SmPC in Greece
- Absence of other neurological disease
- Willingness / ability to provide written informed consent
- Full diagnostic workup for MS in the previous 6 months prior to the inclusion to the study
Who cannot take part
- Concurrent participation in an investigational study in which patient assessment and/or treatment may be dictated by a protocol
- Prior or current use of other DMT
- MS diagnosis >6 months prior to the inclusion to the study
- Patients with history of alcohol or drug abuse that could potentially interfere with their participation in the study
- Age <18 or >50
- Contraindications to use of cladribine tablets according to the Summary of Product Characteristics
- Evidence of progressive MS
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Greece
- Papageorgiou HospitalThessaloniki, GreeceNot yet recruiting
- University General Hospital of Thessaloniki - AHEPAThessaloniki, GreeceNot yet recruiting
About the trial
What the trial wants to find out
The primary endpoint is to assess changes in the immune synapse molecules in naive MS patients treated with cladribine tablets compared to healthy volunteers, at 12-months of treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.
- Plain-language title
- Cladribine Tablets and Immune Cell Contact Molecules in Relapsing Multiple SclerosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-521910-24-00, who can take part
- Record updated
- 3 July 2026